Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
1. Women with operable breast cancer with a 2-8 week preoperative waiting period will
accept preoperative therapy trials and specifically taking a standard drug for breast
cancer such as anastrozole in this study
2. Short term anastrozole treatment will induce measurable changes in biomarker levels (ER,
PR, Her2, Ki67) within the tumor.
3. Degree of response to short term anastrozole varies with a) duration of treatment and b)
breast cancer subtype (based on initial pre-treatment biomarker status)